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Inflammatory cytokines and endogenous anti-oxidants are variables affecting disease progression in
multiple sclerosis (MS). Here we demonstrate the dual capacity of triterpenoids to simultaneously repress
production of IL-17 and other pro-inflammatory mediators while exerting neuroprotective effects directly
through Nrf2-dependent induction of anti-oxidant genes. Derivatives of the natural triterpene oleanolic
acid, namely CDDO-trifluoroethyl-amide (CDDO-TFEA), completely suppressed disease in a murine
model of MS, experimentalautoimmuneencephalomyelitis (EAE),by inhibiting Th1and Th17 mRNA and
cytokine production. Encephalitogenic T cells recovered from treated mice were hypo-responsive to myelin
antigen and failed to adoptively transfer the disease. Microarray analyses showed significant suppression of
pro-inflammatory transcripts with concomitant induction of anti-inflammatory genes including Ptgds and
Hsd11b1.Finally,triterpenoidsinducedoligodendrocytematurationinvitroandenhancedmyelinrepairin
an LPC-induced non-inflammatory model of demyelination in vivo. These results demonstrate the unique
potential of triterpenoid derivatives for the treatment of neuroinflammatory disorders such as MS.
T
he dynamic regulation of cytoprotective genes in response to inflammatory mediators contributes to the
relapsing-remittingnatureofmultiplesclerosis(MS)
1.InmurinemodelsofMS,initiationofdiseaserequires
induction of a Th17 T cell response with disease manifestations ultimately resulting from activated macro-
phages which phagocytose myelin and contribute to degeneration of myelin sheaths, oligodendrocytes and
axons
2. Activated monocytes and macrophages produce inflammatory mediators, including nitric oxide and
reactiveoxygenspecies(ROS),whichcontributetothedevelopmentandprogressionofthedisease
3,4.Generation
of ROS in brain parenchyma contributes to lesion persistence by mediating oligodendroglial damage and axonal
injury
5,6, and reduced serum levels of antioxidants have been observed in patients with MS
7.
The central nervous system is endowed with several protective mechanisms consisting of enzymatic and non-
enzymatic antioxidants whose expression is regulated through the transcription factor nuclear factor-E2-related
factor (Nrf2) and the antioxidant response element (ARE). In humans with MS, enhanced expression of Nrf2/ARE-
regulated antioxidants in the brain is indicative of the response to oxidative stress, and in mice disruption of Nrf2
gene expression (Nrf2
2/2 mice) leads to exacerbation of clinical and pathological symptoms of experimental auto-
immune encephalomyelitis (EAE)
8.N r f 2
2/2 mice are also hypersensitive to LPS-induced neuroinflammation
9 and
Nrf2 is reported to be involved in maintaining CNS myelin
10. To date, over 200 Nrf2/ARE-driven genes involved in
detoxificationand antioxidant defense have been identified, out of which superoxide dismutases (SOD), glutathione
peroxidases, GPxs
11, catalases
4,12,13, and hemeoxygenases-1 (Hmox-1)
14,15 are all modulated during MS.
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emerged as potent regulators of the Nrf2/ARE pathway. Triter-
penoidsrepresentabroadcategoryofmoleculesubiquitouslypresent
intheplantkingdom
16,17,andusedwidelyinAsianmedicine(usually
in the form of herbal extracts)
18. Among these natural triterpenoids,
thenaturalpentacyclictriterpeneoleanolicacid(OA)displaysnumer-
ous biological properties with therapeutic potential
18,19.B o t hO Aa n d
herbal extracts containing OA are known for their immunomodula-
tory properties
20 and have been shown to reduce clinical pathology
associated with neuroinflammation and EAE
21,22.
Oleanolic acid has served as the platform for synthesis of several
novel triterpenoids, including 2-cyano-3,12-dioxooleana-1,9(11)-dien
-28-oic acid methyl ester (CDDO-Me) which is currently in Phase III
clinical trials in patients with diabetic nephropathy
23,24. In preclinical
studies, CDDO-methyl amide (CDDO-MA) was shown to exert neu-
roprotective effects through potent activation of the Nrf2/ARE path-
way and is neuroprotective in preclinical model systems, including a
transgenic model of Alzheimer’s disease
25. Further derivatization of
CDDO to yield an imidazolide (CDDO-Im), an ethyl amide, (CDDO-
EA), or a trifluoroethylamide(CDDO-TFEA), resulted in significantly
increased biological activity
26, and enhanced capacity to cross the
blood brain barrier (BBB)
27.
Inthisstudywerevealthemechanismsmediatingneuroprotective
effects of three CDDO derivatives CDDO-Me, CDDO-EA and
CDDO-TFEA in the treatment of EAE. Daily systemic administra-
tion of these compounds alone significantly alleviates the clinical
symptoms of disease. We show that CDDO-TFEA not only induces
Nrf2 expression and signaling both in affected CNS tissue as well as
in peripheral lymphocytes, but also leads to global suppression of
inflammatory response genes in mice with EAE and suppression
of disease associated cytokines, particularly interleukin-17 (IL-17).
Lastly, CDDO-TFEA protects against non-inflammatory lysopho-
sphatidyl choline (LPC)-induced demyelination suggesting a direct
action of this molecule on myelin preservation and repair. These
results reveal the potency and unique mechanisms through which
novel synthetic triterpenoids, specifically CDDO derivatives, sup-
pressdiseaseprogressioninthesettingofinflammatoryneurodegen-
erative disease.
Results
CDDO derivatives promote complete resolution of EAE. To
investigate the efficacy of selected synthetic triterpenoids (Fig. 1A),
mice were immunized with either MOG 35–55 (C57BL/6 mice) or
PLP (139–151) (Balb/C mice) and received systemic administration
of either CDDO-Me, CDDO-EA, or CDDO-TFEA after the onset of
disease. Administration of triterpenoids every alternate day for 10
days significantly improved survival (Fig 1B) and led to complete
abrogation of clinical symptoms within the first two weeks of
treatment, regardless of disease score at the onset of treatment
(Fig. 1 C). Recrudescence of disease symptoms was significantly
delayed after treatment with CDDO-TFEA, when compared to
CDDO-Me (Fig. S1-A) and CDDO-EA (Fig. S1-B). Re-exposure of
these mice to the same molecule resulted in complete suppression of
clinicalsymptoms in all treatment groups. The severity of symptoms
atdiseaserelapsewaslowandsurvivalwasgreaterthan90%formice
treated with either the ethyl-amide or trifluoroethylamide deriva-
tives. The beneficial effects of CDDO-TFEA were reproducible in
the remitting relapsing model of PLP (139–151)-induced EAE
(Fig. 1D). The effect of these small molecules on EAE disease
progression may involve a combination of suppressive activity on
the peripheral immune system and direct neuroprotective effects
in the CNS. The former is supported by our observation that
lymphocytes collected from mice immunized with MOG (35–55)
and subsequently exposed to CDDO-TFEA completely failed to
adoptively transfer disease to untreated mice (Fig. S2).
CDDO-TFEA attenuates CNS inflammation and demyelination
in mice with EAE. To assess the effects of CDDO-TFEA and other
derivatives on EAE-associated CNS pathology, lumbar spinal cord
and brain stem were obtained from mice either at the peak of disease
Figure 1 | SystemicadministrationofCDDOderivativesamelioratestheseverityofEAE. (A)Chemicalstructureoftheparentmolecule,CDDO,andits
derivatives used in this study. (B) Survival of mice was recorded (Kaplan-Meier survival curve) within 3 months of MOG (35–55) immunization.
(C) C57Bl/6 mice were pooled at different clinical scores and CDDO-TFEA was administered by i.p. injections (as described in methods section) on
alternate days at the indicated time points; a specific clinical score was assigned to each mouse at 48 hr intervals and these scores are depicted as mean
clinical scores. (D) SJL mice were immunized with PLP(139–151) and treated with CDDO-TFEA on alternate days during the indicated time points. All
data are presented as the mean 6 S.E.M. (n5 10–12 mice in each group).
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Independent histological analysis of brain stem (Fig. S3) and spinal
cord demonstrated reduced inflammation (Fig. 2A–C & 2M) and
minimal demyelination (Fig. 2D–F & 2N), in CDDO-TFEA-treated
animals when compared with the untreated control group. There was
a significant reduction in the number of F4/80 (macrophage and
microglia; Fig. 2G–I) and myeloperoxidase (neutrophil, Fig. 2J–L)
positive cells in the lumbar spinal cord of mice treated with CDDO-
TFEA. These data support a conclusion that suppression of immune
and inflammatory cell populations is one mechanism underlying the
response to synthetic triterpenoids in EAE.
Treatment with CDDO-TFEA diminishes inflammatory cytokine
levels.Our laboratory and others haveshown direct suppressive effects
of triterpenoids on immune cell activation and on receptor-mediated
activation of signaling intermediates including Stat3 and NFkB
28,29.T o
determine whether triterpenoid suppression of CNS infiltration by
immune cells in mice with EAE was linked to suppression of the
immune response in the periphery, we first analyzed serum and
supernatants of cultured peripheral blood lymphocytes harvested
from mice with EAE and re-stimulated ex vivo in the presence or
absence of CDDO-TFEA (Fig. 3A–G). A significant reduction in
Th1 and Th17 cytokines (i.e. IL6, IL17, IFNc,T N F a and GMCSF)
was observed while IL-2 production was not altered significantly.
Lymphocytes collected from spleen and inguinal lymph nodes of
mice 21 days after MOG (35–55) injection secreted several cytokines
when restimulated with MOG (35–55) peptide ex vivo, but production
of IL2, IL4, IL6, IL17, TNF-a,I F N - c and GMCSF was significantly
lower in lymphocytes harvested from mice treated with CDDO-TFEA.
When these data were normalized for cell proliferation (to account for
effects of CDDO-TFEA on cell growth) the differences in IL17 and
GMCSF production remained highly significant.
CDDO-TFEA suppresses antigen-specific lymphocyte responses
and modulates Hmox-1 and iNOS protein expression. The data
presented thus far suggest that triterpenoids may suppress EAE
through direct effects on immune cell activation and function. We
hypothesized that CDDO-TFEA might impair development of an
antigen-specific memory response to MOG (35–55) through direct
suppression of T cell activation or cytokine driven proliferative
expansion. Here we show that CDDO-TFEA treatment significantly
inhibited the responses to CD3/CD28 and IL7 both alone and
in combination (Fig. S4). Interleukein-7 (IL7) is a non-redundant
cytokine essential for T cell survival and development and T cell
memory
30. Patients suffering with MS have a higher level of IL7 and
IL7R-alpha in the cerebrospinal fluid compared with patients suffering
from other non-inflammatory neurological disorders
31. CDDO-TFEA
significantly suppressed IL-7 stimulated in vitro proliferation of
both quiescent and activated T cells isolated from spleen and lymph
nodes of mice immunized with MOG (Fig. S4). We assessed the
ex vivo responsiveness of lymphocytes isolated from lymph nodes
and spleen of either a) control mice, b) MOG(35–55)-immunized
mice with symptoms of EAE or c) MOG(35–55)-immunized mice
following treatment with CDDO-TFEA. Lymphocytes derived from
lymphnodesofsymptomaticmicerestimulatedwithMOG(35–55)in
vitro had a more than 5-fold greater proliferative response relative to
control lymphocytes, but this response was significantlydiminished in
culturesoflymphocytesisolatedfrommicetreatedwithCDDO-TFEA
in vivo. In either case, the in vitro treatment of these cells with CDDO-
TFEA completely blocked proliferation in response to MOG (35–55)
(Fig. 4A). These data demonstrate a direct suppression of the
lymphocyte proliferative response to antigen and IL7 stimulation by
CDDO-TFEA and related triterpenoids.
Triterpenoids have also been shown to control inflammation by
suppressing expression of inducible nitric oxide synthase (iNOS) in
Figure 2 | Decreased inflammation and preservation of myelin content after CDDO-TFEA treatment. Mice were sacrificed after MOG (35–55)
immunizationeitheratthepeak ofclinicalsymptomsorataclinicalscoreofzeroandafterrespectivetreatmentswitheithervehiclecontrolorCDDO-TFEA
and CNS tissues were subjected to histopathological analysis. Representative sections of lumbar spinal cord (A–L) from control mice with clinical signs of
EAE or from mice treated with CDDO-TFEA were stained with hematoxilin and eosin to assess inflammation (A–C), with Luxol fast blue to assess myelin
content (D–F), with F4/80 to stain macrophages and microglia (G–I) and with myloperoxidase (MPO) to stain neutrophils (J–L). Arrows indicate
inflammatory cellular infiltrates (B), demyelinated areas (E) and macrophage and neutrophil infiltrates (H & K). A pathologist blinded to subject identity
scored sections taken from eachanimal for(M)inflammation and (N) demyelination onthescale of 0 to 3(Scalebars, 100mm). **,P,0 . 0 1 , S t u d e n t ’ stt e s t .
www.nature.com/scientificreports
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includingcontrols,micewithEAE(atclinicalscore5)andmicewithEAEfollowingtreatmentwithCDDO-derivativesbothatthepeakofdiseaseseverity
and after they reached a clinical score 0. Production of cytokines from peripheral lymphocytes obtained from these mice was determined after culturing
themfor72 hrsexvivo.ELISAwasperformedtodetectcytokinelevelsofIL-2(A),IL-4(B),IL-6(C),IL-17(D),IFNc(E),TNF-a(F)andGMCSF(G).All
data are presented as the mean 6 SEM (n 5 6). **, P , 0.01, *, P , 0.05, Student’s t test.
Figure 4 | CDDO-TFEA inhibits lymphocyte proliferation and modulates iNOS and Hmox-1 protein expression in the CNS of affected mice.
(A)Lymphocyteswerecollectedfromcontrolmice,micewithEAE(atclinicalscore5)orfrommicewithEAEfollowingtreatmentwithCDDO-TFEA(at
clinicalscore0)andculturedfor72 hrsinthepresenceorabsenceofMOG(35–55),withorwithoutCDDO-TFEA.Duringlast16 hrs,
3H-thymidinewas
added to cultures and the incorporated amount of
3H-thymidine in cells was measured as CPM. Protein lysates were prepared from lumbar spinal cord
(B) and brain stem (C) of control mice, mice with EAE (at clinical score 5) or mice with EAE following CDDO-TFEA treatment (at clinical score 0) and
subjectedtoWesternblotanalysistocheckiNOSandHmox-1proteinlevels.Equalloadingofsampleswasconfirmedbyactinimmunodetection.Datais
presented as the mean 6 SEM (n 5 6). ***, P , 0.001, **, P , 0.01, Student’s t test.
www.nature.com/scientificreports
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EAE
32–35, resulting in prolonged exposure to nitric oxide
36 which is
cytotoxic
37 and promotes inflammation
38. We found elevated levels
of iNOS present in the lumbar spinal cord (Fig. 4B) and brain stem
(Fig. 4C) of mice with EAE that were reduced significantly after
CDDO-TFEA treatment. When the same tissues were evaluated
for the expression of Hmox-1, we observed a reciprocal relationship.
Prior reports have shown a link between hemin-induced Hmox-1
expression and reduced clinical severity of EAE in rats, whereas tin
mesoporphyrin, a well-known inhibitor of Hmox-1 markedly exa-
cerbated EAE
15. Moreover, induction of EAE in Hmox1-/- mice led
to enhanced CNS demyelination, paralysis, and mortality
39. The sig-
nificant up-regulation of Hmox-1 protein in brain stem and lumbar
spinal cord after CDDO-TFEA treatment suggests a possible mech-
anismthroughwhichthissmallmolecule maybeexertingneuropro-
tective effects in EAE.
Concomitant regulation of Nrf2-dependent and inflammatory
gene transcription. The observed induction of Hmox-1 protein in
CNS tissues following CDDO-TFEA exposure is consistent with the
ability of the triterpenoids to activate Nrf2-dependent expression of
the Hmox-1 gene. We used real-time PCR to evaluate the expression
of Hmox-1 and several inflammation-related genes (including IFN-
c,IL-17andiNOS)intotalCNStissue(Fig.5A–B)andinsplenocytes
(Fig. 5C) and in mononuclear cells isolated from the CNS (Fig. 5D)
of mice with EAE. A significant increase in Nrf2 and Hmox-1 tran-
scripts was detected in lymphocytes of mice treated with CDDO-
TFEA during the course of disease (Fig. 5A–C), and in mononuclear
cells isolated from the CNS (Fig. 5D). Moreover, CDDO-TFEA
significantly induced Nrf2 and Hmox-1 gene expression by encep-
halitogenic splenocytes cultured in the presence of MOG (35–55)
(Fig. 5C).
The pathogenic role of IL-17 in EAE has been substantiated by
studies in mice deficient in IL-17 or the IL-17-inducing cytokine IL-
23
40,41. We observed complete suppression of IFN-c and IL-17 gene
expression in total CNS tissue (Fig. 5A–B) as well as in mononu-
clear cells isolated from brain stem and lumbar spinal cord (Fig. 5D)
after CDDO-TFEA treatment. Moreover, CDDO-TFEA significantly
reduced both IFN-c and IL-17 expression by lymphocytes isolated
from mice immunized with MOG (35–55), when these cells were re-
exposed to MOG (35–55) in vitro (Fig. 5C). Collectively, these data
highlight the multifunctional nature of the synthetic triterpenoids
and the central role of Nrf2-mediated induction of pathways that
combat oxidative stress, including the Hmox-1 pathway. The data
also suggest the observed triterpenoid effect involves regulation of
immune cells both at the site of disease and in the periphery.
CDDO-TFEA suppresses non-inflammatory LPC-induced
demyelination. The data presented thus far suggests that neuronal
integrity is maintained by CDDO-TFEA during EAE induction.
However, the question remains whether this effect of CDDO-
TFEA is solely due to immune suppression or whether triter-
penoids also exert direct effects on myelin stability or regeneration.
To address this question we utilized the well-established non-
inflammatory lysophosphatidyl choline (LPC)-induced rodent
model of myelin injury. Direct injection of LPC into neural tissue
produces a localized vesicular demyelination of neurons that spares
axons
42. In the LPC-induced demyelination paradigm, a small
amount of exogenous LPC injected into the dorsal columns of the
thoracic spinal cord activates membrane bound phospholipase-A2
which then hydrolyzes the lecithin of myelin leading to membrane
solubilization and demyelination with fully developed lesions at
2 days post-injection
43. To test the efficacy of CDDO-TFEA on
LPC-induced de-myelination, a total of 12 rats were subjected to
LPC injection within dorsal column of spinal cord; 6 of these also
received 10 nM CDDO-TFEA with LPC injection and then again at
thesite of injury 48 hours afterLPC injection.Tissues were removed
7daysfollowinginjuryandprocessed forimmunostaining with anti-
MBP antibody (for myelin), anti-GFAP antibody (for astrocytes) and
anti-NG2 antibody (for oligodendrocytes).
Control mice (injected with PBS) exhibit intact myelin and a nor-
maldistributionofastrocytes(Fig.6A–D)andoligodendrocytes(Fig.
S5A–D). However, at the site of LPC injection neurons were com-
pletely demyelinated (Fig. 6G & Fig. S4G), astrocytes formed a glial
scar around the demylinated area (Fig. 6F and 6H) and oligodendro-
cytes were recruited around demylinated axons (Fig. S5F and S5H).
Figure 5 | CDDO-TFEAtreatmentmodulatesbothantioxidantandinflammatorygenetranscriptionintheCNSandinperipherallymphocytes. Data
represent the fold increase in gene expression levels as detected by quantitative PCR performed on mRNA collected from either (A–B) total CNS tissue,
(C) peripheral lymphocytes or (D) mononuclear cells collected from the CNS tissues of control mice or from those with EAE (at the peak of the disease)
or from mice with EAE following treatment with CDDO-TFEA (when clinical scores returned to baseline). All data are the mean 6 SEM. **,P, 0.01,
Student’s t test.
www.nature.com/scientificreports
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(Fig. 6K and Fig. S5K), with a comparatively normal distribution of
astrocytes and oligodendrocytes. These data were further confirmed
by toluidene blue staining and electron microscopy (Fig. 6M–R). We
observed completely naked axons at the site of LPC injection (Fig. 6N
& 6Q) while administration of CDDO-TFEA preserved myelin at the
site of LPC injection (Fig. 6O and 6R), as defined bythe percentage of
myelinated axons and their G ratios in the dorsal horn of the spinal
cord at the site of LPC injection (Fig. 6S–T).
ThedataaboveindicatethatCDDO-TFEApromotespreservation
ofmyelinatthesiteofinjury,butitisalsopossiblethatCDDO-TFEA
may additionally promote myelin repair by facilitating oligo-
dendrocyte maturation. To address this question, oligodendrocytes
harvested from the CNS of day E18 rat embryos and were cultured
for 10 days in either the presence or absence of CDDO-TFEA.
CDDO-TFEAsignificantlyenhancedmaturationofoligodendrocyte
precursors as shown by expression of maturation markers A2B5
(Fig. 7A–F & 7M) and O4 (Fig. 7G–L & 7N). These data indicate
that during EAE, CDDO-TFEA and related synthetic triterpenoids
actasmultifunctionalagents,bothsuppressingtheimmuneresponse
while also acting directly on neurons to protect them from the
demyelination process and to promote myelin repair.
A unique triterpenoid-modulated transcriptome underlies the
resolution of EAE. To better characterize the triterpenoid mo-
dulated transcriptome in EAE we performed a gene microarray
Figure 6 | CDDO-TFEA is neuroprotecive in the LPC-induced model of demyelination. Immunostaining of tissue sections prepared from dorsal
columnsofthethoracicspinalcordofratsatthesiteofinjectionofeitherPBS(A–D)orLPC(E–H)orLPC1CDDO-TFEA(I–L).Immunohistochemistry
was performed with an anti-MBP antibody (for myelin), anti-GFAP antibody (for astrocytes) and anti-NG2 antibody (for oligodendrocytes). All images
are taken at 200X magnification. Tissue sections prepared from spinal cord segments at sites injected either with LPC or LPC followed by CDDO-TFEA
were subjected to toludene blue staining (M–O) or electron microscopy (P–R) to analyze the myelin content on neurons at the site ofeach lesion. G-ratios
of the axons in dorsal columns (S) and quantification of the percentage of demyelinated and myelinated axons in dorsal columns of spinal cord at the site
of LPC injection (T) are shown here.
www.nature.com/scientificreports
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comparing tissues collected from control mice and from mice
following induction of EAE, with or without exposure to CDDO-
TFEA. A total of 1433 genes were found to be differentially
modulated in mice at the peak of EAE clinical scores compared to
control mice (Fig. 8A). Among them, 135 genes known to be
involved either in the cellular stress response or in inflammation
were significantly altered by CDDO-TFEA treatment, and in most
instances their expression returned to baseline (Fig. 8B–D). How-
ever, the induction of 11b-hydroxysteroid dehydrogenase type 1
(11bHSD1) and of prostaglandin D2 synthase (PGDS) suggests
that activation of steroid and prostaglandin biosynthetic pathways
may contribute to the suppression of CNS inflammation by triter-
penoids. We validated these gene array results by performing real
time PCR on 9 different genes (Fig. 8E). The data suggest that
inflammation driven suppression of both 11bHSD1 and of PGDS
is reversed by exposure to CDDO-TFEA.
Discussion
Multiple mechanisms operant in MS culminate ultimately in the
generation of a highly oxidative microenvironment that is respons-
ible for tissue injury and neurodegeneration
44,45. The data presented
here add to a growing body of literature that strongly support the
clinical development of the family of natural and synthetic triterpe-
noids as chemopreventive and therapeutic agents in the context of
neuro-inflammatory and neurodegenerative diseases, and specif-
ically in the context of MS. While neuroprotective effects of admi-
nistered exogenous antioxidants have been reported in EAE
5,46,
pursuit of strategies that employ newer agents such as synthetic
triterpenoids to induce endogenous enzymatic antioxidants should
be a more efficient means to inhibit the detrimental effects of ROS
and thereby serve as an effective form of chemoprevention for MS.
Synthetic oleanane triterpenoids have emerged as apotent class of
pharmacologic agents capable of strongly inducing the Nrf2-ARE
axis, and this mechanism has been identified as playing a principal
roleintheneuroprotectiveeffectsofCDDOderivativesinavarietyof
modelsofneurodegenerativedisorders
27.Forexample,inthemurine
SOD-1 model of Amyotrophic Lateral Sclerosis (ALS)
47, exposure to
CDDO-EA and CDDO-TFEA results in nuclear translocation of
Nrf2 in cells expressing the SOD-1 mutant, and suppressed disease
progression whether treatment was initiated in asymptomatic mice
or at the onset of clinical manifestations. While the clinical response
observed in the EAE model may be attributed to effects on Nrf2
expression and function, triterpenoids are multifunctional agents
and it is quite likely that multiple targets participate in conferring
protectioninthesettingofacomplexneurodegenerativeprocesslike
MS. For example, a role for Stat3 not only in the genesis of Th17
cells but also in the development of EAE has been defined
48–50. Our
laboratory and others have shown that Stat3 is a direct target of
the synthetic triterpenoids
28,51. Our demonstration that triterpenoid
exposure following induction of EAE significantly represses both
IL-17 mRNA and protein expression suggests that this mechanism
mayalsocontributetotheoverallclinicalresponsetotriterpenoidsin
the EAE model.
ItisnoteworthythatthelinkbetweenaninductionofHmox-1and
repression of the development of a Th17 reponse has also been
demonstrated for other activators of Hmox-1 in preclinical models
of EAE and inflammatory bowel disease (IBD). Hemin, a potent
inducer of Hmox-1 and activator of Nrf2
52, suppresses the develop-
ment of IBD in mice exposed to dextran sodium sulfate (DSS) and
this effect is also associated with a significant reduction in the pro-
duction of IL-17
53. Similarly, intraperitoneal administration of ery-
thropoietin to MOG-EAE mice significantly reduced severity of
disease in a manner that correlated with potent upregulation of
Hmox-1 in the CNS and spleen and with a reduction of Th-17 T cell
subsets
54. Finally, the observation that IL-17 might act to directly
suppress the expression of Hmox-1 in the context of an inflammat-
ory response argues that the balance between these two factors may
in fact be an important determinant of disease expression. Thus
the unique capacity of triterpenoids to simultaneously repress IL-17
Figure 7 | CDDO-TFEA induces early oligodendrocyte maturation. Total brain cells prepared from P3 rat pups were cultured with vehicle (A–C and
G–I) or with 10 nM CDDO-TFEA (D–F and J–L) for 3 days (A, D, G, J), 6 days (B, E, H, K), or 10 days (C, F, I, L). Cells were fixed and immunostained
using antibodies against A2B5 to detect immature oligodendrocyte precursor cells (A–F) or against O4 to detect mature oligodendrocytes (G–L). (Scale
baris100mm).Quantitativeanalysisofthepercentageof(M)A2B5or(N)O4positivecellsafterdifferentdaysofCDDO-TFEAtreatmentisshown.Data
are the mean 6 SEM. **, P , 0.01, *, P , 0.05, Student’s t test.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 201 | DOI: 10.1038/srep00201 7Figure 8 | MicroarrayanalysisofCNStissuesrevealsglobalsuppressionofinflammatorygenesbyCDDO-TFEAinmicewithEAE,withaconcomitant
induction of genes linked to resolution of inflammation. Gene microarray analysis using Ilumina Sentrix array Ref. 8v1.1, using mRNA collected from
lumbarspinalcordofcontrolmiceandmicewithEAEtreatedeitherwithvehiclecontrolorwithCDDO-TFEA.(A)Heatmapof1433genesdifferentially
expressed in EAE mice compared to control mice. (B) Heatmap of 135 genes significantly altered by CDDO-TFEA treatment. (C) Magnified heat map
(from panel B) of genes either down-regulated during EAE or (D) up-regulated during EAE, and their return to baseline after CDDO-TFEA treatment.
(E)QuantitativePCRwasperformedusingselectedprobes(asdescribedinmaterialmethodsection)andRNAcollectedfromaffectedCNStissueofmice
induced to develop EAE and treated with either CDDO-TFEA or vehicle control. b-actin levels were tested to normalize the amount of RNA and relative
fold induction of transcript was calculated by comparing the basal level of expression of selected genes in normal mouse tissues. All data are the
mean 6 SEM. **,P, 0.01, Student’s t test.
www.nature.com/scientificreports
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Nrf-2 suggests their utility for treatment of MS.
It is intriguing to find the induction of both 11b-hydroxysteroid
dehydrogenase type 1 (11bHSD1) and of prostaglandin D2 synthase
(PGDS) in the CNS in mice exposed to CDDO-TFEA. It has been
suggested that a local deficit of cortisol in the CNS may underlie the
relapsing-remitting nature of MS, perhaps secondary to poor local
activationofcortisonevia11b-hydroxysteroiddehydrogenasetype1
(11bHSD1)
55. MS patients have been found to maintain normal cor-
tisolconcentrationsinserumyetexhibitloweredcortisollevelsinthe
CSF during acute relapses. Although 11bHSD1 was not found to be
expressed within active plaques, the significant induction in myelin-
loadedmacrophagesinvitrosuggeststhatproductionofthisenzyme
by infiltrating macrophages may contribute to the self-limiting
nature of MS lesion development. Similarly, a reduction in the in-
trathecal synthesis of prostaglandin D2 synthase (PGDS) has
been documented during acute inflammatory demyelination
56, and
enhanced biosynthesis of prostaglandin (PG)D2 and subsequent
formation of 15-deoxy-D-PGJ2has been implicated in the resolution
of inflammation
57. It is intriguing that 15-PGJ2 has been shown to
activateNrf2signaling andtoinduceHmox-1 inamannersimilarto
CDDO
58 thus demonstrating the capacity to contribute to the endo-
genous anti-oxidant response and raising the question whether the
observed clinical response to triterpenoids shown here might reflect
their capacity to mimic many of the functions of this endogenous
anti-inflammatory protein.
Lastly, our data in the model of LPC-induced demyelination sug-
gest that the efficacy of triterpenoids in the context of EAE is linked
to a capacity to regulate astrocyte activation and to preserve CNS
myelin. Nrf-2-/- mice develop a spontaneous progressive leukoen-
cephalopathy, with vacuolar degeneration that is linked to myelin
unwinding, intramyelinic cysts and oxidative damage to myelin
10.
Similarly, the observation that the anti-oxidant fumaric acid (FA)
can preserve myelin and axonal density has also been linked to the
capacity of FA and its esters to regulate Nrf-2 activity, and may be a
mechanism contributing to the observed reduction of gadolinium
enhancing lesions in MS patients treated with dimethylfumarate
59.
Indeed, the beneficial effects of dimethylfumarate for axon preser-
vation and astrocyte activation in the MOG-EAE model are lost in
mice deficient in Nrf-2 gene expression
60.
In conclusion, the data present here demonstrate the efficacy of
multifunctional triterpenoids in suppressing clinical and pathologic
featuresofdiseaseinpreclinicalmodelsofMS.Thesesmallmolecules
have a unique capacity to simultaneously target intermediates that
drive production of disease-inducing cytokines, such as IL-17, while
inducing neuroprotective pathways activated through Nrf-2. Thus,
synthetictriterpenoidsmayserveasboththerapeuticandchemopre-
ventiveagentsinthecontextofneurodegenerativeandinflammatory
diseases affecting the CNS.
Methods
Animals. C57BL/6 and SJL female mice (for EAE studies) and male Wistar rats (for
LPC studies) were housed in a pathogen free animal facility in standard cages with
free access to food and water in climate and light controlled rooms. All experimental
procedures were approved by the Animal Care and Use Committee of the Case
Western Reserve University.
EAE induction. EAE was induced in 10–12 weeks old, age matched female mice by
subcutaneousimmunizationonbothflankswith200mlofemulsioncontainingeither
Complete Fruend’s adjuvant (100 ml of incomplete Fruend’s adjuvant with 8 mg/ml
of Mycobacterium Tuberculosis and 100 ml of PBS) (DIFCO Laboratories) or
Complete Fruend’s adjuvant with 200 mg of MOG (35–55). At the time of injection
and 48 hours later 200 ng of pertussis toxin (List Biological Laboratories) was
injectedintrapertoniallyin100mlofPBS.Miceweremonitoredfordailyclinicalsigns
of EAE and the following criteria were used to grade clinical scores: 0-no signs of
disease;
1-limp tail; 2-moderate hind-limb weakness; 3-severe hind-limb weakness;
4-Complete hind limb paralysis; 5- quadriplegia or premoribund state; 6-death.
Drug treatment. CDDO-Me, CDDO-EA or CDDO-TFEA were dissolved in a
minimal amount of DMSO to obtain 10 mM stock and further dissolved in 7.5%
PBST(7.5 mlTween-80dissolvedin100 mlofPBS)toobtainafinalconcentrationof
100 nM. Animals were injected with 100 ml of this solution by intra-peritoneal (i.p.)
injectionattheintervalof48 hoursforatotalof5injections.Therapywasinitiatedin
micewithvaryingseverityofdiseaseasnotedbydifferentclinicalscores,startingafter
15 days of MOG-35-55 immunization. Control animals were injected with a similar
volume of vehicle i.e. 7.5% PBST.
Histology and immunohistochemistry. On day 18 to 23 (at clinical scores 4 to 5
in control mice with EAE) and at clinical score 0 in recipients of CDDO-TFEA
treatment, mice were anesthetized and perfused with phosphate buffer saline (PBS)
followed with 4% paraformaldehyde in PBS (PFA-PBS). Brain and spinal cord were
collected and fixed in 4% PFA-PBS and embedded in paraffin to obtain 5 mm thick
sections. At least 10 to 12 serial sections were obtained from 4 different regions of the
brain (rostral cerebrum, mid cerebrum, mid brain and cerebellum with brain stem).
Spinalcordwasdividedinto3parts(cervical,thoracicandlumbar).Atleast5sections
from each part and longitudinal serial sections of all regions were obtained for
representationoftheentirespinalcord.Tissuesectionswerestainedwithhematoxilin
&eosin(H&E)toassessroutine histologyandinflammationandalsowithLuxolFast
BlueandthePeriodicAcidSchiffreagenttoanalyzemyelincontent.Eachsectionwas
assigned a histological score for inflammation and demylenation from 0 to 3 by an
observer blinded to sample identity, where 0 represents no lesions,
1- moderate and 3 represents severe lesions. Spinal cord sections were
immunostainedwithantimyloperoxidaseantibodytodetectgranulocytesinfiltration
and anti-F4/80 antibody for macrophage and microglia.
Western blot analysis. Animals were sacrificed for tissue collection at different time
points after immunization and drug treatment. Brain (further divided into forebrain,
midbrain and hindbrain) and spinal cord (further divided into cervical, thoracic and
lumbar) were collected and snap frozen. Tissue homogenates were prepared in lysis
buffer,consistingofT-PER,tissueprotein extractionreagent(Pierce,Rockford, IL),a
protease inhibitor cocktail tablet (Roche, Mannheim, Germany) and 15100 diluted
phosphatase inhibitor mixtures I and II (Sigma, St. Louis, MO). Proteins were
denatured and equal amounts of proteins were electrophoresed in 4–12% bis-Tris/
polyacrylamide gels (NuPAGE; Invitrogen, Carlsbad, CA) and transferred to
nitrocellulose membranes with 0.2 mm pores (Invitrogen). The membranes were
blocked for 2 h in blocking solution (TBScontaining 10% nonfat dry milkand 0.05%
Tween20)andincubated overnightat4uCwithprimaryantibodydilutedinblocking
solution. Incubation with horseradish peroxidase-conjugated secondary antibody
was performed at room temperature for 1 h, and immunoreactivity was detected by
using enhanced chemiluminescence (Pierce, Rockford, IL).
Oligodendrocyte primary culture. Dissociated brain cultures were made from
Sprague-Dawley rat pups at postnatal day 3, plated on poly-L-lysine/Laminin coated
coverslips and grown in 1% fetal bovine serum in DMEM supplemented with
GlutaMAX
TM, Penicillin-Streptomycin, Hong’s N2 and PDGF-AA. Treatment with
vehicle (control) or vehicle 1 10 nM CDDO-TFEA began one day after dissociation
and lasted for three, six or ten days in vitro. Immunocytochemical markers of the
oligodendrocyte lineages were assayed, including A2B5 (for immature
oligodendrocyte precursor cells), and O4, (for mature marker of oligodendrocyte
precursor cells).Atotalof100to300totalcells werecountedfromfivedifferentareas
in each culture and positive immunoreactive cells for A2B5 or O4 were plotted as
percentage of total cells.
Antibodies. The rabbit polyclonal anti-iNOS and anti-Hmox-1 (Santa Cruz
Biotechnology,Santa Cruz, CA) were used for Western blot analysis
(15200). For immunohistochemistry 2mg/ml of rabbit polyclonal
anti-myeloperoxidase (lot 373A603A (1); Lab Vision; Fremont, CA), or 10 mg/ml
of the rat IgG2b MAb F4/80 (clone C1:A3-1; Serotec; Raleigh, NC) were used.
Secondary horseradishperoxidase-conjugated antibodies were obtained from
AmershamBiosciences (Piscataway, NJ) and used at 152000 dilution for
immunoblots analysis and 2.5 mg/ml biotinylated rabbit anti-rat IgG secondary
antibody (Vector Laboratories; Burlingame, CA) to detect F4/80 and 2.5 mg/ml
biotinylated goat anti-rabbit IgG secondary antibody (Vector) to detect
myeloperoxidase.
ELISA. Serum levels of IL-2, Il-4, IL-6, GM-CSF, TNF and IFN-c were detected with
OptiEIA Elisa sets (BD Biosciences and IL-17 was detected with DuoSet ELISA
development System (R&D systems) as per manufacturer’s suggested protocol.
Ex vivo restimulation of T cells. Mice immunized with or without MOG(35-55)
(clinical score-5) or CDDO-TFEA treated (clinical score-0) were sacrificed and a
single cell suspension was prepared from draining lymph nodes (Inguinal and
brachial) and restimulated with 33 mg/ml of MOG (35–55) in presence or absence of
CDDO-TFEA and 50 ng/ml mIL7. Cells were seeded in a 96 well plate at a density of
2310
5. After 72 hours culture supernatants were collected for analysis of cytokine
secretionandcellswereusedforRNApreparation. Forproliferationassays,0.5mciof
(
3H) thymidine was added in cultures during last 12 hours and thymidine
incorporation was measured as cell proliferation.
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for this study. Demyelination in the spinal cord was induced by LPC injection as
described previously
30 with subtle modification in protocol. In brief, animals were
anesthetizedwith5 mlperkgofbodyweightof0.2 mlketamine(FortDodge),0.1 ml
xylazine (Lloyd Laboratories) and 0.7 ml of distilled water. After shaving and
cleaning with ethanol and betadine, a T10 laminectomy was performed in a
stereotactic apparatus (Stoelting). Using a 30-mm glass micropipette attached to a
Nano-injector (World Precision Instruments), 1.5 ml of 1% freshly prepared LPC
(Sigma)solutionwasinfusedat15 ml/hour.Theneedlewaskeptinplacefor5 minto
preventreflux;theskinwasclosedandtreatedwithBetagen(Med-Pharmex).Inorder
to rule out any mechanical injury control rats were subjected to similar surgical
process but in spite of LPC similar volume of PBS was injected. Rats received either
10 nM CDDO-TFEA or vechicle control at the time of LPC injection and again after
48 hours at the site of LPC injection. After 7 days all animals were sacrificed and
targeted spinal cord tissue was collected and processed for electron microscopy (for
analyzingthemyelincontent)andfrozentissuesectionswereusedforimmunostaing
toanalyzemyelincontentandrecruitmentofoligodendrocyteandglialcellsatthesite
of injury.
Electron microscopy. We anesthetized and perfused the animals with Sorenson’s
buffer followed by solution containing 4% paraformaldehyde (wt/vol) and 2.5%
glutararaldehyde (vol/vol). Spinal cords were sliced into 1–2-mm sections and post-
fixed in the same solution overnight at 4uC, after which sections were embedded in
Araldite resin. Semi-thin sections were stained with 1% Toluidine blue staining
(wt/vol) at 65uC for a few seconds, washed several times with water and then
dehydratedandmountedwithPermount.Thinsectionswerecut,stainedwithuranyl
acetate and lead citrate and analyzed. G ratios (defined as the diameter of the axon
divided by the diameter of the axon and myelin) were calculated from the outer
perimeter of the axon divided by the total perimeter of the axon and myelin. Six
pictures were randomly chosen for each mouse and 100–200 fibers per picture were
calculated.Atleast6miceperstrainpertimepointwereanalyzed.Thedataareshown
as G ratio and total number of myelinated fibers.
Oligonucleotide microarray analysis. Total RNA was isolated using Trizol reagent
(Invitrogen) and RNeasy (Qiagen) from control and EAE mice lumbar spinal cord,
treated with or without CDDO-TFEA. Each tissue sample was derived from a
different individual mouse giving three true biological replicate samples. The yield
was quantified using NanoDrop ND-1000 Spectrophotometer (Nanodrop
Technologies,Delaware)andqualitycheckedbyconventionaldenaturing1%agarose
gel analysis. For microarray analysis, extracted total RNA was biotinylated and
amplified using the IluminaH TotalPrep RNA Amplification Kit. Labeled cRNA was
then hybridized with IluminaSentrixH array (Sentrix Mouse Ref 8v1.1) according to
theirstandardprotocol(Illumina).Followinghybridizationandwashing,arrayswere
scannedusingIluminaBeadStudio(version3.1).Therawdatafromallthearrayswere
then exported out and analyzed using GeneSpring 7.3.1 (Agilent Technologies).
Expression of all genes on a chip was normalized globally to the expression value of
themedianofthechipandeachgenenormalizedacrossconditionstoamedianof1.0.
This approach reduced the expression ratio for every gene in each of the control
samples to 1 and set the expression ratio for each gene in each test sample to a value
indicative of its expression relative to that in the corresponding control. The
normalizeddatawerethenfilteredbyvolcanoplottoidentifygeneswhoseexpression
(inallthreebiologicalreplicates)appearstobeup-ordown-regulatedbyanarbitrary
cutoffofatleast1.5foldwithp-value50.05.Statisticalanalysiswasperformedonthe
logexpressionratiosutilizingonewayStudentst-testanalysisofvariancewithoutany
multiple testing correction. No post-hoc analysis was applied.
Quantitative Real-time polymerase chain reaction. 10 ml of total RNA
(2 micrograms) from each sample were reverse transcribed using High-Capacity
cDNAReverseTranscriptionKits(AppliedBiosystems)thatcontains10XRTBuffer;
25X dNTP Mix (100 mM); 10RT Random Primers; Multiscribe
TM; Reverse
Transcriptase and nuclease-free water in a final volume of 20 ml reaction mixture.
Reversetranscriptionwasperformedusingthefollowingprogramonathermalcycler
(Applied Biosystems) using only 1 cycle: (step 1)a t2 5 uC for 10 min; (step 2)a t3 7 uC
for 120 min; (step 3)a t8 5 uC for 5 sec; and (step 4)a t4 uC for infinity. QRT-PCR was
performed with an ABI 7500 system (Applied Biosystems) tovalidate the microarray
results on a number of genes apparently exhibiting differential expression. Pre-
synthesized primers specific for the genes purchased from ABI are shown in Table 1.
1. Noseworthy, J. H., Lucchinetti, C., Rodriguez, M. & Weinshenker, B. G. Multiple
sclerosis. N Engl J Med 343, 938–952 (2000).
2. Gutcher, I., et al. Autocrine transforming growth factor-beta1 promotes in vivo
Th17 cell differentiation. Immunity 34, 396–408 (2011).
3. Benveniste,E.N.Cytokineactionsinthecentralnervoussystem.CytokineGrowth
Factor Rev 9, 259–275 (1998).
4. Ruuls, S. R., et al. Reactive oxygen species are involved in the pathogenesis of
experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 56,
207–217 (1995).
5. Gilgun-Sherki, Y., Melamed, E. & Offen, D. The role of oxidative stress in the
pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J
Neurol 251, 261–268 (2004).
6. Smith, K. J., Kapoor, R. & Felts, P. A. Demyelination: the role of reactive oxygen
and nitrogen species. Brain Pathol 9, 69–92 (1999).
7. vanMeeteren,M.E.,Teunissen,C.E.,Dijkstra,C.D.&vanTol,E.A.Antioxidants
and polyunsaturated fatty acids in multiple sclerosis. Eur J Clin Nutr 59,
1347–1361 (2005).
8. Johnson, D. A., Amirahmadi, S., Ward, C., Fabry, Z.& Johnson,J. A. The absence
of the pro-antioxidant transcription factor Nrf2 exacerbates experimental
autoimmune encephalomyelitis. Toxicol Sci 114, 237–246 (2010).
9. Innamorato, N. G., et al. The transcription factor Nrf2 is a therapeutic target
against brain inflammation. J Immunol 181, 680–689 (2008).
10.Hubbs, A.F., etal.Vacuolar leukoencephalopathywith widespread astrogliosis in
mice lacking transcription factor Nrf2. Am J Pathol 170, 2068–2076 (2007).
11. Tajouri, L., et al. Quantitative and qualitative changes in gene expression patterns
characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res
119, 170–183 (2003).
12. Guy, J., Qi, X. & Hauswirth, W. W. Adeno-associated viral-mediated catalase
expression suppresses optic neuritis in experimental allergic encephalomyelitis.
Proc Natl Acad Sci U S A 95, 13847–13852 (1998).
13. Singh, I., et al. Impaired peroxisomal function in the central nervous system with
inflammatory disease of experimental autoimmune encephalomyelitis animals
and protection by lovastatin treatment. Brain Res 1022, 1–11 (2004).
14. Liu, Y., Liu, J., Tetzlaff, W., Paty, D. W. & Cynader, M. S. Biliverdin reductase,
a major physiologic cytoprotectant, suppresses experimental autoimmune
encephalomyelitis. Free Radic Biol Med 40, 960–967 (2006).
15. Liu, Y., et al. Heme oxygenase-1 plays an important protective role in
experimental autoimmune encephalomyelitis. Neuroreport 12, 1841–1845
(2001).
16. Connolly, J. D. & Hill, R. A. Triterpenoids. Nat Prod Rep 18, 560–578 (2001).
17. Xu, R., Fazio, G. C. & Matsuda, S. P. On the origins of triterpenoid skeletal
diversity. Phytochemistry 65, 261–291 (2004).
18. Dzubak, P., et al. Pharmacological activities of natural triterpenoids and their
therapeutic implications. Nat Prod Rep 23, 394–411 (2006).
19. Liu, J. Oleanolic acid and ursolic acid: research perspectives. J Ethnopharmacol
100, 92–94 (2005).
Table 1 | Quantitative PCR probes
Genes of interest Assay ID* Common Name
IL-17a Mm00439619_m1 interleukin 17A
NOS-2 Mm01309902_m1 Nitric oxide synthase 2
IFN-c Mm99999071_m1 hemeoxygenase 1
Hmox-1 Mm00516007_m1 interferon gamma
Nrf-2 Mm03053465_s1 nuclear receptor subfamily 2, group F, member 2
Ptgds Mm01330614_g1 PGD2; PGDS
Grin3b Mm00504568_m1 NR3B
Stat2 Mm00490880_m1 AW496480
Cd68 Mm00839636_g1 gp110; Scard1
Csf3r Mm00432735_m1 Cd114; Csfgr; G-CSFR
Tgfbr1 Mm00436971_m1 ALK5; Alk-5; TbetaRI
Hsd11b1 Mm00476182_m1 Hsd11b1
Cd74 Mm00658576_m1 Ii; CLIP; DHLAG
Cd84 Mm00488934_m1 CDw84; SLAMF5
b-Actin Mm00607939_s1
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 201 | DOI: 10.1038/srep00201 1020. Raphael, T. J. & Kuttan, G. Effect of naturally occurring triterpenoids glycyrrhizic
acid, ursolic acid, oleanolic acid and nomilin on the immune system.
Phytomedicine 10, 483–489 (2003).
21. Martin, R., et al. Beneficial actions of oleanolic acid in an experimental model of
multiple sclerosis: a potential therapeutic role. Biochem Pharmacol 79, 198–208
(2010).
22.Tran, T.A.,McCoy,M.K.,Sporn,M.B.& Tansey,M.G.The synthetictriterpenoid
CDDO-methyl ester modulates microglial activities, inhibits TNF production, and
provides dopaminergic neuroprotection. J Neuroinflammation 5, 14 (2008).
23. Pergola, P. E., et al. Effect of bardoxolone methyl on kidney function in patients
with T2D and Stage 3b-4 CKD. Am J Nephrol 33, 469–476 (2011).
24. Pergola, P. E., et al. Bardoxolone methyl and kidney function in CKD with type 2
diabetes. N Engl J Med 365, 327–336 (2011).
25. Dumont, M., et al. Triterpenoid CDDO-methylamide improves memory and
decreases amyloid plaques in a transgenic mouse model of Alzheimer’s disease. J
Neurochem 109, 502–512 (2009).
26. Liby, K. T., Yore, M. M. & Sporn, M. B. Triterpenoids and rexinoids as
multifunctional agents for the prevention and treatment of cancer. Nat Rev
Cancer 7, 357–369 (2007).
27. Stack, C., et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl
amide improve the behavioral phenotype and brain pathology in a transgenic
mouse model of Huntington’s disease. Free Radic Biol Med 49, 147–158 (2010).
28. Liby, K., et al. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT
phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin
Cancer Res 12, 4288–4293 (2006).
29. Yore, M. M., Liby, K. T., Honda, T., Gribble, G. W. & Sporn, M. B. The synthetic
triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks
nuclear factor-kappaB activation through direct inhibition of IkappaB kinase
beta. Mol Cancer Ther 5, 3232–3239 (2006).
30. Bayer, A. L., Lee, J. Y., de la Barrera, A., Surh, C. D. & Malek, T. R. A function for
IL-7R for CD41CD251Foxp31 T regulatory cells. J Immunol 181, 225–234
(2008).
31. Lundmark, F., et al. Variation in interleukin 7 receptor alpha chain (IL7R)
influences risk of multiple sclerosis. Nat Genet 39, 1108–1113 (2007).
32. Cross, A. H., et al. Inducible nitric oxide synthase gene expression and enzyme
activity correlate with disease activity in murine experimental autoimmune
encephalomyelitis. J Neuroimmunol 71, 145–153 (1996).
33. Koprowski, H., et al. In vivo expression of inducible nitric oxide synthase in
experimentally induced neurologic diseases. Proc Natl Acad Sci U S A 90,
3024–3027 (1993).
34. Lin, R. F., Lin, T. S., Tilton, R. G. & Cross, A. H. Nitric oxide localized to spinal
cords of mice with experimental allergic encephalomyelitis: an electron
paramagnetic resonance study. J Exp Med 178, 643–648 (1993).
35.Okuda,Y.,etal.Expressionoftheinducibleisoformofnitricoxidesynthaseinthe
central nervous system of mice correlates with the severity of actively induced
experimental allergic encephalomyelitis. J Neuroimmunol 62, 103–112 (1995).
36. Xie, Q. & Nathan, C. The high-output nitric oxide pathway: role and regulation. J
Leukoc Biol 56, 576–582 (1994).
37. Henry, Y., et al. Nitric oxide, a biological effector. Electron paramagnetic
resonance detection of nitrosyl-iron-protein complexes in whole cells. Eur
Biophys J 20, 1–15 (1991).
38. Ialenti, A., Ianaro, A., Moncada, S. & Di Rosa, M. Modulation of acute
inflammation by endogenous nitric oxide. Eur J Pharmacol 211, 177–182 (1992).
39. Chora, A. A., et al. Heme oxygenase-1 and carbon monoxide suppress
autoimmune neuroinflammation. J Clin Invest 117, 438–447 (2007).
40. Chen, Y., et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and
ameliorates autoimmune encephalomyelitis. J Clin Invest 116, 1317–1326 (2006).
41. Hofstetter, H. H., et al. Therapeutic efficacy of IL-17 neutralization in murine
experimental autoimmune encephalomyelitis. Cell Immunol 237, 123–130 (2005).
42.Smith,K.J.&McDonald,W.I.Spontaneousandmechanicallyevokedactivitydue
to central demyelinating lesion. Nature 286, 154–155 (1980).
43.Fuller,M.L.,etal.Bonemorphogeneticproteinspromotegliosisindemyelinating
spinal cord lesions. Ann Neurol 62, 288–300 (2007).
44. Gonsette, R. E. Oxidative stress and excitotoxicity: a therapeutic issue in multiple
sclerosis? Mult Scler 14, 22–34 (2008).
45. Witherick, J., Wilkins, A., Scolding, N. & Kemp, K. Mechanisms of oxidative
damage in multiple sclerosis and a cell therapy approach to treatment.
Autoimmune Dis 2011, 164608 (2010).
46. van Meeteren, M. E., Hendriks, J. J., Dijkstra, C. D. & van Tol, E. A. Dietary
compounds prevent oxidative damage and nitric oxide production by cells
involved in demyelinating disease. Biochem Pharmacol 67, 967–975 (2004).
47. Neymotin, A., et al. Neuroprotective effect of Nrf2/ARE activators, CDDO
ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic
lateral sclerosis. Free Radic Biol Med 51, 88–96 (2011).
48. Jadidi-Niaragh, F. & Mirshafiey, A. Th17 cell, the new player of
neuroinflammatory process in multiple sclerosis. Scand J Immunol 74, 1–13
(2011).
49. Jin, W., Zhou, X. F., Yu, J., Cheng, X. & Sun, S. C. Regulation of Th17 cell
differentiationandEAEinductionbyMAP3KNIK.Blood113,6603–6610(2009).
50. Ogura, H., et al. Interleukin-17 promotes autoimmunity by triggering a positive-
feedback loop via interleukin-6 induction. Immunity 29, 628–636 (2008).
51. Ahmad, R., Raina, D., Meyer, C. & Kufe, D. Triterpenoid CDDO-methyl ester
inhibitstheJanus-activatedkinase-1(JAK1)--.signaltransducerandactivatorof
transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.
Cancer Res 68, 2920–2926 (2008).
52. Kim, Y. C., et al. Hemin-induced activation of the thioredoxin gene by Nrf2. A
differential regulation of the antioxidant responsive element by a switch of its
binding factors. J Biol Chem 276, 18399–18406 (2001).
53. Zhong, W., et al. Hemin exerts multiple protective mechanisms and attenuates
dextran sulfate sodium-induced colitis. J Pediatr Gastroenterol Nutr 50, 132–139
(2010).
54. Chen, S. J., et al. Erythropoietin enhances endogenous haem oxygenase-1 and
represses immune responses to ameliorate experimental autoimmune
encephalomyelitis. Clin Exp Immunol 162, 210–223 (2010).
55. Heidbrink, C., et al. Reduced cortisol levels in cerebrospinal fluid and differential
distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis:
implications for lesion pathogenesis. Brain Behav Immun 24, 975–984 (2010).
56. Huang, Y. C., et al. Decreased intrathecal synthesis of prostaglandin D2 synthase
in the cerebrospinal fluid of patients with acute inflammatory demyelinating
polyneuropathy. J Neuroimmunol 206, 100–105 (2009).
57. Rajakariar, R., et al. Hematopoietic prostaglandin D2 synthase controls the onset
and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14
PGJ2. Proc Natl Acad Sci U S A 104, 20979–20984 (2007).
58. Ikeda, Y., et al. Suppression of rat thromboxane synthase gene transcription by
peroxisome proliferator-activated receptor gamma in macrophages via an
interaction with NRF2. J Biol Chem 275, 33142–33150 (2000).
59. Gold, R., Linker, R. A. & Stangel, M. Fumaric acid and its esters: An emerging
treatment for multiple sclerosis with antioxidative mechanism of action. Clin
Immunol (2011).
60. Linker, R. A., et al. Fumaric acid esters exert neuroprotective effects in
neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134,
678–692 (2011).
Acknowledgments
We are thankful to Janet Robinson and Jennifer Alabran for their expert technical support
and helpful discussions. We also thank NUS, Singapore for providing travel support for
Dr. Pareek. This work was supported by the intramural funds from CWRU and The Case
Research Institute. Dr. Letterio would like to thank Jane and Lee Seidman for their support
through their endowment for Pediatric Cancer Innovation.
Authors contribution
J.J.L. and T.K.P. conceived and coordinated the study, designed the experiments, analyzed
the data and wrote the manuscript, T.K.P. carried out major biochemical and biological
experiments, A.B carried out LPC studies, S.K. and S.L.L. performed and analyzed
microarray experiments, A.Z. carried out OPC maturation experiments, L.B. helped with
PLP-EAEexperiments,M.L.C.performedhistopathologicalanalyses,C.M.,K.T.L.,R.H.M.,
M.B.S., T.K.P. and J.J.L. discussed the hypothesis and interpreted the data.
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: A patent application (US 2009/0060873/A1) is pending
related to use of synthetic triterpenoids in treatment of multiple sclerosis.
License: This work is licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this
license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
How to cite this article: Pareek, T.K. et al. Triterpenoid modulation of IL-17 and Nrf-2
expression ameliorates neuroinflammation and promotes remyelination in autoimmune
encephalomyelitis. Sci. Rep. 1, 201; DOI:10.1038/srep00201 (2011).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 201 | DOI: 10.1038/srep00201 11